Intellia Therapeutics, Inc.
NTLA
$12.28
$0.080.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.05M | 23.02M | 13.78M | 14.25M | 16.63M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.05M | 23.02M | 13.78M | 14.25M | 16.63M |
| Cost of Revenue | 80.74M | 73.63M | 78.95M | 80.53M | 108.43M |
| Gross Profit | -65.69M | -50.61M | -65.17M | -66.29M | -91.80M |
| SG&A Expenses | 34.84M | 48.10M | 46.31M | 43.71M | 29.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.58M | 121.73M | 125.26M | 124.24M | 137.43M |
| Operating Income | -100.53M | -98.71M | -111.48M | -110.00M | -120.81M |
| Income Before Tax | -96.23M | -95.79M | -101.32M | -101.26M | -114.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.23M | -95.79M | -101.32M | -101.26M | -114.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.23M | -95.79M | -101.32M | -101.26M | -114.33M |
| EBIT | -100.53M | -98.71M | -111.48M | -110.00M | -120.81M |
| EBITDA | -98.33M | -96.33M | -109.06M | -107.52M | -118.31M |
| EPS Basic | -0.81 | -0.83 | -0.92 | -0.98 | -1.10 |
| Normalized Basic EPS | -0.50 | -0.50 | -0.59 | -0.62 | -0.68 |
| EPS Diluted | -0.81 | -0.83 | -0.92 | -0.98 | -1.10 |
| Normalized Diluted EPS | -0.50 | -0.50 | -0.59 | -0.62 | -0.68 |
| Average Basic Shares Outstanding | 118.49M | 115.92M | 110.19M | 103.73M | 103.50M |
| Average Diluted Shares Outstanding | 118.49M | 115.92M | 110.19M | 103.73M | 103.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |